We add value by understanding our sectors inside out, and release regular industry research and reports

HealthTech Heartbeat – Q1 2018 Market Review

By Henry Barnes 10 Apr 2018

Welcome to the Q1 2018 edition of the HealthTech Heartbeat – Results International’s quarterly market update of the HealthTech segment covering both Biopharma and Healthcare IT.


Biopharma IT has helped engineer a strong quarter for the HealthTech public market with the index achieving a 21.2% quarterly increase. Veeva (+32.1%) and Instem (+71.4%) outperformed analyst revenue estimates in their respective full year earnings reports, with the former trading at a sector high 13x revenue and spearheading investor appetite in the sector. Instem’s significant increase can also be attributed to securing a contract with a top five global CRO to outsource all of its data set generation. Tabula Rasa was the quarter’s top performing stock over the LTM period (187.8%+) with an increase due to strong financial performance since IPO

Read More

Total deal volume remains consistent with the previous quarter at a total of 55 transactions, outperforming the same quarter in 2017. There were two high-profile $1bn+ transactions in the quarter: healthcare analytics provider Inovalon, which has conducted one technology acquisition a year since going public in 2015, executed its biggest deal to date with the $1.2bn purchase of ABILITY Network from Summit Partners. However, it was Roche Holdings that led the way following its acquisition of the remaining 87.4% stake in Flatiron for $1.9bn, surpassing Blue Apron as New York’s top venture capital-backed exit, demonstrating the value healthcare conglomerates will pay for applied data-driven technology.

UK-based Healthcare IT company Medopad provided one of the larger UK-based fundraisings in recent years and has been tipped to reach “unicorn” status in research reports. Having received an initial $28m in Series A funding, Medopad, an AI patient monitoring platform, is targeting $120m in equity capital over the coming months after securing over $100m of commercial projects and partnerships in China following Theresa May’s meeting with China’s President Xi – most notably the partnership with Tencent, China’s largest technology business. Medopad is definitely one to watch in the upcoming HealthTech Heartbeat editions as a potential IPO candidate.

M&A activity in the sector remains healthy and fundraising appetite strong. As a result, now is a good time to be contemplating fundraising, exit or growth through acquisition in the HealthTech space – if you are, please do get in touch.

Read Less

Henry Barnes


Contact Henry

Get in Touch

Talking is a more rewarding experience than reading

If you would like to have an informal conversation about how we work, or simply to discuss the next stage of your company’s development, please contact us.

View Global Offices     SUBSCRIBE

Connect with us

Follow Results International on Twitter Follow Results International on LinkedIn Follow Results International on Facebook

Your Nearest Office